- DocumentJDRF Therapeutic Venturestéléversé parsstrumello7395
- DocumentGeneral Foods Corporate Timelinetéléversé parsstrumello7395
- DocumentJDRF, Less Until Nonetéléversé parsstrumello7395
- DocumentWhy Big Pharmaceutical Companies’ Current Nanotech Efforts Should Failtéléversé parsstrumello7395
- DocumentNovo Nordisk Congressional Testimony on Follow-On Biopharmaceuticals Mollerup March 26, 2007téléversé parsstrumello7395
- DocumentEmblem Insulin Formulary Change 2010téléversé parsstrumello7395
- DocumentWhy Nonprofits Fund For-Profit Companies Doing Drug Researchtéléversé parsstrumello7395
- DocumentAgaMatrix & Sanofi-Aventis Enter Global Diabetes Partnershiptéléversé parsstrumello7395
- DocumentHuman insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptorstéléversé parsstrumello7395
- DocumentFDA ISO Standards for BG Meters 06-24-2009téléversé parsstrumello7395
- DocumentBeyond 'I'm a Diabetic', Little Common Groundtéléversé parsstrumello7395
- DocumentHalozyme Therapeutics, Inc. 2009 Investor Day Presentationtéléversé parsstrumello7395
- DocumentJDRF Countdown July 2009téléversé parsstrumello7395
- Document2008-03-24_Asset_EN Paper on Follow-On Biologics Jan. 2007téléversé parsstrumello7395
- Document2008-03-24_Asset_PCMA Summary of en Studytéléversé parsstrumello7395
- DocumentInfluence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabeticstéléversé parsstrumello7395
- DocumentThe Unique Cytoarchitechture of Human Pancreatic Islets Has Implications for Islet Cell Functiontéléversé parsstrumello7395
- DocumentStatement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings on "Follow-On Biopharmaceuticals"téléversé parsstrumello7395
- DocumentMost Commercial Insulin Assays Fail to Detect Recombinant Insulin Analoguestéléversé parsstrumello7395
- DocumentHow Do We Define Cure of Diabetes?téléversé parsstrumello7395
- DocumentExpanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin isotopetéléversé parsstrumello7395
- DocumentCould Generic Insulin Soon Hit the U.S. Market?téléversé parsstrumello7395
- DocumentClass Action Complaint for Negligence, Products Liability and Punitive Damages Against Eli Lilly & Company and Novo Nordisk A/S Re; Biosynthetic Human Insulintéléversé parsstrumello7395
- DocumentMandated Diabetes Registries Will Not Benefit Persons With Diabetestéléversé parsstrumello7395
- DocumentDetermination of Purity and Identification of Animal Sources of Insulin in Various Insulin Preparationstéléversé parsstrumello7395
- DocumentPeter Van Etten JDRF Letter Retéléversé parsstrumello7395
- DocumentTreatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearstéléversé parsstrumello7395
- DocumentDifferent Potencies of Biosynthetic Human and Purified Porcine Insulintéléversé parsstrumello7395
- DocumentQuestions Answers &téléversé parsstrumello7395
- DocumentStem Cells and Diabetestéléversé parsstrumello7395
- DocumentFederal Funding of Stem Cell Researchtéléversé parsstrumello7395